Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pelthos Therapeutics ( (PTHS) ) just unveiled an announcement.
On May 14, 2026, Pelthos Therapeutics reported first-quarter 2026 results showing continued commercial momentum for ZELSUVMI, which generated $10.7 million in net product revenue, up 17% from the fourth quarter of 2025, with 7,884 units prescribed by 3,228 unique prescribers and a 25% increase in units dispensed. Since its July 2025 launch, ZELSUVMI has produced $26.9 million in net sales, supported by a larger sales force now at 64 territory managers, a $50 million term loan facility from Horizon Technology Finance of which $30 million was drawn, and a $32 million March 31 cash balance, even as Pelthos narrowed its net loss to $10.2 million while continuing to invest heavily in SG&A and preparing for future commercialization of XEPI and XEGLYZE.
First-quarter 2026 financials showed stable cost of goods sold at $1.7 million, higher interest expense tied to convertible notes and the Horizon facility, and a $5.2 million fair value adjustment on convertible debt, resulting in an adjusted EBITDA loss of $8.0 million compared with a $7.6 million loss in the prior quarter. These results highlight Pelthos’ strategy of using expanded commercial infrastructure and new financing to grow its dermatology franchise, improve operating leverage over time, and position itself for additional product launches, while current losses and increased expenses underscore ongoing execution and financing risks for investors and other stakeholders.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
Spark’s Take on PTHS Stock
According to Spark, TipRanks’ AI Analyst, PTHS is a Neutral.
The score is held down primarily by weak financial performance (large losses and continued cash burn despite improved revenue and margins) and limited valuation support due to unprofitability. Technicals are roughly neutral. Corporate updates are a relative positive, reflecting early product uptake, portfolio expansion, and financing actions that improve near-term operating runway.
To see Spark’s full report on PTHS stock, click here.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on differentiated cutaneous infectious disease products addressing unmet patient needs. Its lead product, ZELSUVMI, is the first at-home FDA-approved prescription therapy for molluscum contagiosum, and its portfolio also includes XEPI for impetigo and XEGLYZE for head lice.
Average Trading Volume: 12,566
Technical Sentiment Signal: Strong Buy
Current Market Cap: $91.4M
For an in-depth examination of PTHS stock, go to TipRanks’ Overview page.